top of page

Topic:

Osteogenesis Imperfecta

Issue:

​

Category:

Congenital

Title:

Assessing the Safety and Efficacy of Tranexamic Acid Usage in Osteogenesis Imperfecta Patients

Author:

Eaton, Vincent BS; Braaten, Marco BS; Schissel, Makayla BS, MPH; Wallace, Maegen MD

Journal:

Journal of Pediatric Orthopaedics

Date:

January 2024

Reference:

44(1): p e73-e78, DOI: 10.1097/BPO.0000000000002524

Level Of Evidence:

III

# of Patients:

30 patients (TXA group), 30 patients (control group)

Study Type:

Retrospective cohort study

Location:

Not specified

Summary:

The study evaluates the safety and efficacy of tranexamic acid (TXA) in reducing intraoperative blood loss in children with Osteogenesis Imperfecta (OI), a condition that often requires orthopedic surgeries and is associated with increased bleeding.

Methods:

TXA-treated patients were matched 1:1 with non-TXA-treated controls based on age, bone category, and OI type. Data were analyzed using Fisher Exact Test and Wilcoxon Rank Sum test for comparison of transfusion rates, blood loss, and postoperative stay.

Exclusions:

Patients who did not meet the matching criteria (age, bone category, OI Type) or had incomplete data were excluded.

Results:

TXA group had no transfusions required, compared to 20% of controls (P=0.02). Median estimated blood loss (EBL) was significantly lower in TXA group (20 mL vs. 62.5 mL, P=0.0004). Median postoperative stay was shorter for TXA patients (2.6 days vs. 4 days, P=0.001).

Conclusions:

The study supports the use of TXA in OI patients to reduce perioperative blood loss and transfusion rates, recommending its standard use in this patient population.

Relevance:

Limitations:

Perspective:

bottom of page